Unknown PHASE1 INTERVENTIONAL 2-arm NCT04507971

Effects of MET-3 and MET-5 on Gut Microbiome and Metabolic Function in Men and Women With Hypertriglyceridemia

Sponsor: NuBiyota

Conditions Obesity, Metabolically Benign

Interventions MET-3

Updated 5 times since 2020 Last updated: Aug 7, 2020 Started: Jun 22, 2020 Primary completion: Dec 31, 2021 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Obesity, Metabolically Benign and is currently ongoing. NuBiyota leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Nov 2022 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Nov 2022 [monthly]

Recruiting PHASE1
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE1

First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NuBiyota

Data source: NuBiyota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada